Literature DB >> 3060794

Meth A fibrosarcoma cells express two transforming mutant p53 species.

D Eliyahu1, N Goldfinger, O Pinhasi-Kimhi, G Shaulsky, Y Skurnik, N Arai, V Rotter, M Oren.   

Abstract

Expression plasmids directing the synthesis of various forms of the p53 cellular tumor antigen were compared with respect to their biological activities. All plasmids encoding wild type p53, derived from two different cDNA libraries, had absolutely no detectable activity when assayed for transformation of primary rat embryo fibroblasts in collaboration with Ha-ras. In contrast, p53 variants carrying point mutations in the protein coding region exhibited at least some transforming activity. Most notably, this was true for both types of mutant p53 cDNA clones isolated from Meth A cells. The data indicate that these cells, derived from a chemically-induced tumor, carry two independently mutated p53 alleles, each encoding a transformationally activated protein. This may imply that the mutations in the p53 gene played a role in the development of the Meth A tumor. Finally, cells overexpressing a transfected mutant p53 exhibit a physical complex between this exogenous p53 and its endogenous counterpart, possibly resulting in the stabilization of the latter.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3060794

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  70 in total

1.  Different regulation of the p53 core domain activities 3'-to-5' exonuclease and sequence-specific DNA binding.

Authors:  F Janus; N Albrechtsen; U Knippschild; L Wiesmüller; F Grosse; W Deppert
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

2.  p53 functions as a cell cycle control protein in osteosarcomas.

Authors:  L Diller; J Kassel; C E Nelson; M A Gryka; G Litwak; M Gebhardt; B Bressac; M Ozturk; S J Baker; B Vogelstein
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

3.  Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding.

Authors:  E Shaulian; A Zauberman; D Ginsberg; M Oren
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

4.  Mutation of the casein kinase II phosphorylation site abolishes the anti-proliferative activity of p53.

Authors:  D M Milne; R H Palmer; D W Meek
Journal:  Nucleic Acids Res       Date:  1992-11-11       Impact factor: 16.971

5.  How many mutant p53 molecules are needed to inactivate a tetramer?

Authors:  Wan Mui Chan; Wai Yi Siu; Anita Lau; Randy Y C Poon
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

6.  Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis.

Authors:  G Shaulsky; N Goldfinger; A Ben-Ze'ev; V Rotter
Journal:  Mol Cell Biol       Date:  1990-12       Impact factor: 4.272

7.  The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia.

Authors:  H Ahuja; M Bar-Eli; Z Arlin; S Advani; S L Allen; J Goldman; D Snyder; A Foti; M Cline
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

8.  Stabilization of the p53 transformation-related protein in mouse fibrosarcoma cell lines: effects of protein sequence and intracellular environment.

Authors:  O Halevy; A Hall; M Oren
Journal:  Mol Cell Biol       Date:  1989-08       Impact factor: 4.272

9.  Expression of p53 product in Chinese human bladder carcinoma.

Authors:  D W Ye; J F Zheng; S X Qian; Y J Ma
Journal:  Urol Res       Date:  1993-05

Review 10.  The first 30 years of p53: growing ever more complex.

Authors:  Arnold J Levine; Moshe Oren
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.